Invitae Stock Forecast, Price & News

Invitae (NYSE:NVTA) Frequently Asked Questions

Is Invitae a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae or view top-rated stocks.

How has Invitae's stock been impacted by Coronavirus?

Invitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVTA stock has increased by 11.3% and is now trading at $17.64.
View which stocks have been most impacted by COVID-19.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Invitae.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) released its quarterly earnings data on Sunday, November, 7th. The medical research company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.22. The medical research company earned $114.40 million during the quarter, compared to the consensus estimate of $126.56 million. Invitae had a negative trailing twelve-month return on equity of 23.02% and a negative net margin of 155.87%. The business's quarterly revenue was up 66.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.62) EPS.
View Invitae's earnings history.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $450 million-$475 million, compared to the consensus revenue estimate of $484.54 million.

What price target have analysts set for NVTA?

8 Wall Street analysts have issued twelve-month price objectives for Invitae's shares. Their forecasts range from $25.00 to $58.00. On average, they anticipate Invitae's stock price to reach $40.63 in the next twelve months. This suggests a possible upside of 130.3% from the stock's current price.
View analysts' price targets for Invitae or view top-rated stocks among Wall Street analysts.

Who are Invitae's key executives?

Invitae's management team includes the following people:

• Sean Emerson George, Chairman, President & Chief Executive Officer
• Kenneth D. Knight, Chief Operating Officer
• Roxi Wen, Chief Financial Officer
• Robert Nussbaum, Chief Medical Officer
• Layton Wedgeworth, Chief Technology Officer

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

Who are some of Invitae's key competitors?

Some companies that are related to Invitae include Guardant Health (GH), Natera (NTRA), Elekta AB (publ) (EKTAY), Veracyte (VCYT), Fulgent Genetics (FLGT), CareDx (CDNA), RadNet (RDNT), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), Genetron (GTH), Personalis (PSNL), Renalytix AI (RNLX), DermTech (DMTK), Progenity (PROG) and Viridian Therapeutics (VRDN).
View all of NVTA's competitors.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (7.88%), Nikko Asset Management Americas Inc. (7.88%), Macquarie Group Ltd. (3.28%), Wellington Management Group LLP (2.02%), Perceptive Advisors LLC (1.73%) and Geode Capital Management LLC (1.53%). Company insiders that own Invitae stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae.

Which institutional investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Goldman Sachs Group Inc., Hsbc Holdings PLC, Millennium Management LLC, Barclays PLC, Victory Capital Management Inc., New York State Common Retirement Fund, and Artisan Partners Limited Partnership. Company insiders that have sold Invitae company stock in the last year include Artur Bergman, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae or view top insider-selling stocks.

Which institutional investors are buying Invitae stock?

NVTA stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Macquarie Group Ltd., Fisher Asset Management LLC, Rock Springs Capital Management LP, Guggenheim Capital LLC, and Wolverine Asset Management LLC.
View insider buying and selling activity for Invitae or or view top insider-buying stocks.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $17.64.

How much money does Invitae make?

Invitae has a market capitalization of $3.99 billion and generates $279.60 million in revenue each year. The medical research company earns $-602.17 million in net income (profit) each year or ($3.45) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 2,100 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

Where are Invitae's headquarters?

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at (415) 374-7782 or via email at [email protected].